Numerai GP LLC Has $2.71 Million Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Numerai GP LLC decreased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 33.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,555 shares of the biotechnology company's stock after selling 2,327 shares during the period. Axon Enterprise accounts for approximately 0.7% of Numerai GP LLC's holdings, making the stock its 18th biggest holding. Numerai GP LLC's holdings in Axon Enterprise were worth $2,707,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in AXON. New Wave Wealth Advisors LLC acquired a new position in Axon Enterprise during the 4th quarter valued at about $40,000. Y.D. More Investments Ltd acquired a new position in Axon Enterprise during the 4th quarter valued at about $45,000. Stonebridge Financial Group LLC acquired a new position in Axon Enterprise during the 4th quarter valued at about $53,000. GPS Wealth Strategies Group LLC lifted its position in Axon Enterprise by 74.1% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 40 shares during the period. Finally, Berbice Capital Management LLC bought a new stake in shares of Axon Enterprise in the 4th quarter valued at about $59,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on AXON shares. Needham & Company LLC upped their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Northcoast Research cut Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Barclays upped their price target on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. The Goldman Sachs Group upped their price target on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and an average target price of $652.73.

Axon Enterprise Stock Up 0.7%

NASDAQ AXON traded up $4.79 during trading hours on Friday, reaching $733.18. 419,101 shares of the company's stock were exchanged, compared to its average volume of 759,084. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $735.68. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The company's 50-day moving average is $584.61 and its two-hundred day moving average is $594.51. The company has a market capitalization of $57.08 billion, a price-to-earnings ratio of 189.45, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the firm posted $1.15 EPS. The business's revenue was up 31.3% on a year-over-year basis. On average, analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, President Joshua Isner sold 9,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $683.31, for a total value of $6,149,790.00. Following the completion of the sale, the president now owns 308,714 shares of the company's stock, valued at approximately $210,947,363.34. This represents a 2.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Matthew R. Mcbrady sold 400 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $718.40, for a total value of $287,360.00. Following the completion of the sale, the director now directly owns 3,492 shares of the company's stock, valued at approximately $2,508,652.80. The trade was a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,764 shares of company stock valued at $14,856,635 in the last quarter. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.